GlassScriptPhysician profile
Destiny Moore Moss
NPI 1972997179
$8,816.98
in general payments reported to CMS, 2019-2025
41 companies · $2,581 in 2025
The $2,581 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,973 · 2022: $1,748 · 2023: $1,359 · 2024: $1,156 · 2025: $2,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,776 · Travel and Lodging: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,775.79 |
| Travel and Lodging | $1,320.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,947.45 | 2022-2025 | Axonics, Ams 700, Watchman Flx |
| Coloplast Corp | $1,661.06 | 2021-2025 | Speedicath, Altis |
| Astellas Pharma US INC | $563.38 | 2021-2025 | Myrbetriq, Xtandi, Veozah |
| Antares Pharma, INC. | $560.67 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Abbvie INC. | $490.30 | 2021-2025 | |
| Janssen Biotech, INC. | $477.21 | 2021-2025 | Erleada, Akeega |
| Cipla USA INC. | $373.01 | 2021 | |
| Rochester Medical Corporation | $301.62 | 2021-2022 | |
| Urogen Pharma, INC. | $227.27 | 2023-2025 | Jelmyto |
| Pfizer INC. | $211.19 | 2021-2025 | |
| Axonics, INC. | $167.74 | 2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $163.72 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $156.16 | 2022-2025 | Keytruda, Lynparza |
| Procept Biorobotics Corporation | $116.08 | 2023 | Aquabeam Robotic System |
| Myovant Sciences INC. | $103.74 | 2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $102.79 | 2021-2023 | |
| Clarus Therapeutics INC. | $92.93 | 2021 | |
| Convatec INC. | $84.53 | 2021-2024 | |
| Tolmar Pharmaceuticals, INC. | $83.65 | 2021 | |
| Dendreon Pharmaceuticals LLC | $82.63 | 2021-2025 | Provenge |
| Urovant Sciences INC | $76.49 | 2021-2022 | |
| Genzyme Corporation | $75.30 | 2022 | |
| Progenics Pharmaceuticals, INC. | $70.56 | 2023-2025 | Pylarify |
| Endo USA, INC. | $66.46 | 2024-2025 | Aveed, Xiaflex |
| Medtronic, INC. | $66.36 | 2023-2025 | Interstim |
| C. R. Bard, INC. & Subsidiaries | $63.54 | 2025 | Magic3 Go Intermittent Urinary Catheter, Bard Urinary Drainage Bag |
| Ferring Pharmaceuticals INC. | $58.95 | 2025 | Adstiladrin |
| Olympus America INC. | $56.32 | 2022-2025 | Itind System |
| Abc Home Medical Supply, INC. | $49.41 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $44.83 | 2022 | |
| Tolmar, INC. | $38.44 | 2023-2024 | |
| Blue Earth Diagnostics | $36.26 | 2021-2023 | |
| Halozyme INC | $24.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $21.58 | 2025 | Opdivo |
| Baxter Healthcare | $18.97 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.87 | 2022 | |
| Davol INC. | $15.22 | 2025 | Arista |
| Angiodynamics, INC. | $13.95 | 2025 | Nanoknife |
| 180 Medical, INC. | $13.54 | 2025 | Gentlecath |
| Allergan, INC. | $12.37 | 2021 | |
| Ambu INC. | $9.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Destiny Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.